Registry Watch
An agent reads the trial registry, in the open
Every weekday a machine pulls one slice of ClinicalTrials.gov, compares it field by field against the copy it pulled last time, and commits the difference. This page is that output, unedited. No number on it was typed by a person.
- Studies in the slice
- 7,945
- Runs on record
- 20
- Registry snapshot
- 2026-09-24
- Retrieved
- 2026-09-25
Industry-sponsored interventional trials matching the modality query below.
Weekday harvests since 2026-08-18. The registry does not publish at weekends.
ClinicalTrials.gov dataTimestamp 2026-09-24T09:00:05 -- the registry's own clock.
Pulled 09:21:11 UTC, about twenty minutes after publication.
The slice, stated exactly
A watch over "biotech" would be a watch over nothing in particular. This one is a query, and the query is the definition -- industry-sponsored interventional trials of the modalities where a registry delta is usually a manufacturing story.
- filter.advanced
- AREA[LeadSponsorClass]INDUSTRY AND AREA[StudyType]INTERVENTIONAL
- query.intr
- cell therapy OR gene therapy OR CAR-T OR mRNA OR siRNA OR antisense OR oligonucleotide
Served by https://clinicaltrials.gov/api/v2/studies. The projection keeps 19 fields per study; everything else in the registry record is deliberately dropped, and the dropped part is where the blind spot below lives.
The run ledger
One bar per harvest, counting the studies whose projected fields moved. The tall early bars are not busier weeks; they are wider windows, from runs that spanned several registry days. A diff always compares the last committed corpus against now, so a missed night costs the intermediate state, never the delta.
| Snapshot | Studies | Touched | Changes | In | Out |
|---|---|---|---|---|---|
| 2026-09-24 | 7,945 | 32 | 79 | 0 | 1 |
| 2026-09-23 | 7,946 | 31 | 69 | 4 | 0 |
| 2026-09-22 | 7,942 | 28 | 68 | 2 | 0 |
| 2026-09-21 | 7,940 | 28 | 75 | 6 | 0 |
| 2026-09-18 | 7,934 | 36 | 112 | 3 | 0 |
| 2026-09-17 | 7,931 | 36 | 61 | 6 | 0 |
| 2026-09-16 | 7,925 | 21 | 51 | 1 | 0 |
| 2026-09-15 | 7,924 | 22 | 57 | 1 | 0 |
| 2026-09-14 | 7,923 | 28 | 69 | 3 | 0 |
| 2026-09-11 | 7,920 | 48 | 129 | 1 | 0 |
| 2026-09-10 | 7,919 | 35 | 74 | 3 | 1 |
| 2026-09-09 | 7,917 | 49 | 83 | 4 | 1 |
| 2026-09-08 | 7,914 | 33 | 58 | 5 | 1 |
| 2026-09-04 | 7,910 | 74 | 133 | 4 | 1 |
| 2026-09-02 | 7,907 | 108 | 177 | 9 | 1 |
| 2026-08-28 | 7,899 | 133 | 251 | 7 | 2 |
| 2026-08-25 | 7,894 | 120 | 198 | 7 | 0 |
| 2026-08-19 | 7,887 | 44 | 80 | 2 | 0 |
| 2026-08-18 | 7,885 | 62 | 117 | 4 | 0 |
What is in the slice
Recruitment status
- completed3,161
- recruiting1,274
- terminated1,079
- unknown867
- active not recruiting772
- not yet recruiting400
- withdrawn293
- suspended55
One value per study, over 7,945. Bars scale to the largest row in this panel.
Phase
- phase23,773
- phase13,529
- phase31,570
- na424
- phase4200
- early phase1197
A trial registered as PHASE1/PHASE2 is counted under both, so these exceed the study count.
Lead sponsor
- novartis pharmaceuticals216
- merck sharp & dohme llc204
- hoffmann-la roche189
- astrazeneca176
- pfizer145
- eli lilly and company125
- glaxosmithkline105
- amgen98
Top eight of the industry sponsors in the slice; the tail is long and is not shown.
Country
- united states4,174
- china1,908
- spain1,451
- france1,313
- germany1,289
- united kingdom1,277
- italy1,178
- canada1,139
Locations are projected as a country SET, so a 40-site trial counts once per country.
The latest run, field by field
79 field changes across the snapshot published 2026-09-24, grouped by field in a fixed order that is the same every day. The order is the page’s one editorial act and it applies to fields, never to trials: nothing here decides that a particular study matters.
status
3- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING -> COMPLETED
- NCT06601504Hutchmed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
ACTIVE_NOT_RECRUITING -> COMPLETED
- NCT07368959Aurion Biotech
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
RECRUITING -> ACTIVE_NOT_RECRUITING
enrollment
5- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
count 18, type ESTIMATED -> count 7, type ACTUAL
- NCT05949125AvenCell Europe GmbH
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
count 80, type ESTIMATED -> count 37, type ESTIMATED
- NCT06270316UniQure Biopharma B.V.
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
count 12, type ESTIMATED -> count 20, type ESTIMATED
- NCT07368959Aurion Biotech
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
count 120, type ESTIMATED -> count 130, type ACTUAL
- NCT07482176Adverum Biotechnologies, Inc.
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
count 284, type ESTIMATED -> count 534, type ESTIMATED
has results
1- NCT04669808Sirnaomics
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
false -> true
endpoint hash
3- NCT04669808Sirnaomics
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
sha256:2c17f8d3a82551be -> sha256:fc2e906cd466bb55
- NCT05949125AvenCell Europe GmbH
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
sha256:00313fe9f1b10e9e -> sha256:f1528eaf01709e59
- NCT06270316UniQure Biopharma B.V.
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
sha256:9f37a8a286839034 -> sha256:a8145ef90c44f998
title
2- NCT04115761Ever Supreme Bio Technology Co., Ltd.
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients -> Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
- NCT05949125AvenCell Europe GmbH
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies -> Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
sponsor
1- NCT04671433MeiraGTx Ocular UK Ltd
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Janssen Research & Development, LLC -> MeiraGTx Ocular UK Ltd
countries
1- NCT05748171Pfizer
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Slovakia, Spain, Sweden, Switzerland -> Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, Switzerland
start date
1- NCT07654283AusperBio Therapeutics Inc.
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
2026-08-27 -> 2026-09-01
primary completion
4- NCT04115761Ever Supreme Bio Technology Co., Ltd.
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
date 2026-12-30, type ESTIMATED -> date 2027-12-30, type ESTIMATED
- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
date 2026-08, type ESTIMATED -> date 2026-06-25, type ACTUAL
- NCT06062420GlaxoSmithKline
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
date 2026-09-01, type ESTIMATED -> date 2026-09-10, type ACTUAL
- NCT06601504Hutchmed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
date 2026-05-12, type ESTIMATED -> date 2026-05-23, type ACTUAL
completion
5- NCT04115761Ever Supreme Bio Technology Co., Ltd.
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
date 2026-12-30, type ESTIMATED -> date 2027-12-30, type ESTIMATED
- NCT04624204Merck Sharp & Dohme LLC
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
date 2027-10-28, type ESTIMATED -> date 2027-11-15, type ESTIMATED
- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
date 2026-08, type ESTIMATED -> date 2026-06-25, type ACTUAL
- NCT06270316UniQure Biopharma B.V.
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
date 2031-04-30, type ESTIMATED -> date 2031-11-30, type ESTIMATED
- NCT06601504Hutchmed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
date 2026-11-12, type ESTIMATED -> date 2026-05-23, type ACTUAL
last update posted
32registry housekeeping -- a re-attestation, not a decision- NCT04042025Novartis Gene Therapies
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
2025-04-25 -> 2026-09-24
- NCT04115761Ever Supreme Bio Technology Co., Ltd.
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
2024-09-19 -> 2026-09-24
- NCT04624204Merck Sharp & Dohme LLC
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
2026-09-10 -> 2026-09-24
- NCT04669808Sirnaomics
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
2024-03-18 -> 2026-09-24
- NCT04671433MeiraGTx Ocular UK Ltd
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
2026-03-16 -> 2026-09-24
- NCT05215340Daiichi Sankyo
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
2026-08-19 -> 2026-09-24
- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
2025-04-04 -> 2026-09-24
- NCT05727904Iovance Biotherapeutics, Inc.
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
2026-06-26 -> 2026-09-24
- NCT05748171Pfizer
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
2026-08-14 -> 2026-09-24
- NCT05878860Atsena Therapeutics Inc.
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
2026-09-21 -> 2026-09-24
- NCT05885555Novartis Pharmaceuticals
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
2026-09-11 -> 2026-09-24
- NCT05949125AvenCell Europe GmbH
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
2025-05-14 -> 2026-09-24
- NCT06047379Neonc Technologies, Inc.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
2026-09-15 -> 2026-09-24
- NCT06062420GlaxoSmithKline
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
2026-06-24 -> 2026-09-24
- NCT06270316UniQure Biopharma B.V.
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
2025-10-23 -> 2026-09-24
- NCT06439277Eli Lilly and Company
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
2026-09-04 -> 2026-09-24
- NCT06447662Pfizer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
2026-07-22 -> 2026-09-24
- NCT06496178Merus B.V.
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
2026-08-31 -> 2026-09-24
- NCT06601504Hutchmed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
2025-06-06 -> 2026-09-24
- NCT06693336ToLymph Inc.
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
2026-09-17 -> 2026-09-24
- NCT06890598Eli Lilly and Company
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
2026-09-08 -> 2026-09-24
- NCT07148089Solid Biosciences Inc.
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
2026-08-10 -> 2026-09-24
- NCT07197788Endogenex, Inc.
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
2026-08-18 -> 2026-09-24
- NCT07222267BeOne Medicines
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
2026-08-14 -> 2026-09-24
- NCT07368959Aurion Biotech
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
2026-05-22 -> 2026-09-24
- NCT07391670AstraZeneca
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
2026-08-25 -> 2026-09-24
- NCT07468071Novartis Pharmaceuticals
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
2026-09-23 -> 2026-09-24
- NCT07482176Adverum Biotechnologies, Inc.
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
2026-07-15 -> 2026-09-24
- NCT07543055Regeneron Pharmaceuticals
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
2026-09-23 -> 2026-09-24
- NCT07654283AusperBio Therapeutics Inc.
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
2026-08-26 -> 2026-09-24
- NCT07828353Regend Therapeutics
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
2026-09-18 -> 2026-09-24
- NCT07833202Shanghai Jeyou Pharmaceutical Co., Ltd.
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
2026-09-22 -> 2026-09-24
status verified
21registry housekeeping -- a re-attestation, not a decision- NCT04042025Novartis Gene Therapies
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
2025-04 -> 2026-09
- NCT04115761Ever Supreme Bio Technology Co., Ltd.
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
2024-09 -> 2026-09
- NCT04669808Sirnaomics
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
2024-03 -> 2026-08
- NCT04671433MeiraGTx Ocular UK Ltd
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
2026-03 -> 2026-09
- NCT05215340Daiichi Sankyo
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
2026-08 -> 2026-09
- NCT05667649Regeneration Biomedical, Inc.
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
2025-04 -> 2026-09
- NCT05727904Iovance Biotherapeutics, Inc.
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
2026-06 -> 2026-09
- NCT05748171Pfizer
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
2026-08 -> 2026-09
- NCT05949125AvenCell Europe GmbH
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
2025-05 -> 2026-09
- NCT06047379Neonc Technologies, Inc.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
2026-07 -> 2026-09
- NCT06062420GlaxoSmithKline
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
2026-06 -> 2026-09
- NCT06270316UniQure Biopharma B.V.
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
2025-10 -> 2026-09
- NCT06447662Pfizer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
2026-07 -> 2026-09
- NCT06601504Hutchmed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
2025-06 -> 2026-09
- NCT07148089Solid Biosciences Inc.
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
2026-08 -> 2026-09
- NCT07197788Endogenex, Inc.
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
2026-08 -> 2026-09
- NCT07222267BeOne Medicines
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
2026-08 -> 2026-09
- NCT07368959Aurion Biotech
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
2026-05 -> 2026-09
- NCT07391670AstraZeneca
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
2026-08 -> 2026-09
- NCT07482176Adverum Biotechnologies, Inc.
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
2026-07 -> 2026-09
- NCT07654283AusperBio Therapeutics Inc.
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
2026-08 -> 2026-09
Who joined, who left
Entered the slice (0)
None in this run.
Left the query (1)
Left the QUERY, never the registry. A sponsor edit can re-rank a study out of a free-text match, and so can ranking drift under a record nobody touched.
NCT04844073
Merged by the registry (0)
None in this run. A merge is a duplicate registration folded into a surviving id -- not a departure, though a diff that ignores aliases reports it as one.
What this instrument cannot see
A demo that showed only its successes would be the wrong demo. These are the standing limits, each one measured rather than guessed.
- Most registry edits never reach this page. A one-time census on 2026-09-10 (documented in
scripts/registry-watch/README.md, "What is projected") resolved 280 of 282 blind edits across 246 distinct studies via the registry’s per-study history API: 88% were site churn or re-verification, and 72% touched contacts and locations -- which the projection reduces to a country set by design. Adding one field, the sponsor’s re-attestation date, cut the blind spot from 56% to 17% in that run. A dated historical measurement, not a figure this page recomputes. - Run detail goes back 19 runs, recovered; run counts go back 20. Until 2026-09-25 this read the other way. Deltas are overwritten each morning, so detail lived only in git -- and three squash merges collapsed days one through sixteen into four commits, discarding the states between. The recovery worked because a merged pull request’s original commits stay reachable under
refs/pull/<n>/head. Every run came back, and the check that the recovery is complete rather than merely large is arithmetic: each archived run’s touched count, recomputed from its own events, matches the ledger entry for entry. Runs are archived as they happen now. - A study leaving the query has not left the registry. A free-text match can be broken by a sponsor’s own edit or by ranking drift under an untouched record, and the two are not separable without asking the API about every departure. The field is named for what it observes.
- An upstream schema change would look like registry-wide news. So a run that touches more than a fifth of the slice, or ten times the trailing median, halts and writes nothing rather than publishing the loudest possible false positive.
Method: scripts/registry-watch/build_feed.py reduces the committed corpus, deltas and history into the feed this page renders; no figure is hand-entered and the page performs no runtime fetch. Registry snapshot 2026-09-24T09:00:05 (ClinicalTrials.gov dataTimestamp), retrieved 2026-09-25T09:21:11.456Z, diffed 2026-09-25T09:21:25.111Z. Feed built 2026-09-25T09:21:25.111Z. Counts describe what the projection observes, which is narrower than the registry record itself.